Related Experiment Video

Updated: Jul 2, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity

Alexandros Ardavanis1, Stella Koumna, Ioannis Fragos

  • 1First Department of Medical Oncology, St. Savvas Anticancer Hospital, Athens, Greece. ardavanis@yahoo.com

Anticancer Research
|August 30, 2008
PubMed
Abstract

Insights

Erlotinib demonstrated efficacy in pretreated advanced non-small cell lung cancer (NSCLC) patients. Patients with good performance status experienced improved progression-free survival and overall survival with erlotinib treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) treatment research involves epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
  • Erlotinib (Tarceva) is a key EGFR TKI investigated for NSCLC efficacy and survival impact.

Purpose of the Study:

  • To retrospectively assess the efficacy of erlotinib in advanced NSCLC.
  • To evaluate the impact of erlotinib on patient survival outcomes.

Main Methods:

  • Retrospective study including 36 patients with stage IIIB or IV advanced/recurrent metastatic NSCLC.
  • Erlotinib 150 mg daily administered at various treatment lines.
  • Analysis of progression-free survival (PFS) and overall survival (OS).

Main Results:

  • Median PFS was 4 months; median OS was 7 months.
  • Patients with ECOG performance status 0 or 1 showed significantly better PFS and OS.
  • Overall response rate was 16.7%, with a disease control rate of 81%.

Conclusions:

  • Erlotinib is effective in pretreated advanced NSCLC patients.
  • Good performance status is associated with better outcomes.
  • Erlotinib is well-tolerated in this patient population.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...